| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.80 [0.72, 0.90] | | < 1 | | 0% | 3 studies (3/-) | 100.0 % | some concern | not evaluable | moderate | crucial | - |
| progression or deaths (PFS) | 0.71 [0.55, 0.92] | | < 1 | | 86% | 3 studies (3/-) | 99.6 % | some concern | not evaluable | moderate | important | - |
| objective responses (ORR) | 1.41 [0.75, 2.66] | | > 1 | | 90% | 2 studies (2/-) | 85.5 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.81 [0.21, 3.04] | | < 1 | | 32% | 2 studies (2/-) | 62.4 % | some concern | not evaluable | moderate | non important | - |
| AE (grade 3-4) | 1.38 [0.93, 2.05] | | < 1 | | 67% | 2 studies (2/-) | 5.7 % | some concern | not evaluable | moderate | non important | - |
| AE leading to death (grade 5) | 1.03 [0.65, 1.62] | | < 1 | | 0% | 2 studies (2/-) | 45.1 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (any grade) | 1.38 [1.09, 1.75] | | < 1 | | 0% | 2 studies (2/-) | 0.4 % | some concern | not evaluable | moderate | non important | - |
| SAE (any grade) | 1.52 [1.23, 1.89] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
| STRAE (any grade) | 1.68 [1.16, 2.43] | | < 1 | | 45% | 2 studies (2/-) | 0.3 % | some concern | not evaluable | moderate | non important | - |
| TRAE (any grade) | 1.26 [0.52, 3.06] | | < 1 | | 72% | 2 studies (2/-) | 30.5 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 1.55 [1.20, 1.99] | | < 1 | | 28% | 2 studies (2/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 1.49 [0.64, 3.48] | | < 1 | | 2% | 2 studies (2/-) | 17.8 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 1.00 [0.06, 16.09] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
| Alopecia TRAE (grade 3-4) | 0.70 [0.04, 11.23] | | < 1 | | 0% | 2 studies (2/-) | 59.8 % | some concern | not evaluable | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 1.39 [0.92, 2.09] | | < 1 | | 33% | 2 studies (2/-) | 5.9 % | some concern | not evaluable | moderate | non important | - |
| Arthralgia TRAE (grade 3-4) | 0.75 [0.17, 3.37] | | < 1 | | 0% | 1 study (1/-) | 64.6 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 0.76 [0.24, 2.44] | | < 1 | | 48% | 2 studies (2/-) | 67.5 % | some concern | not evaluable | moderate | non important | - |
| Colitis TRAE (grade 3-4) | 2.53 [0.49, 13.10] | | < 1 | | 0% | 1 study (1/-) | 13.6 % | NA | not evaluable | | non important | - |
| Constipation TRAE (grade 3-4) | 0.99 [0.08, 12.92] | | < 1 | | 0% | 2 studies (2/-) | 50.3 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 1.41 [0.34, 5.85] | | < 1 | | 31% | 2 studies (2/-) | 31.8 % | some concern | not evaluable | moderate | non important | - |
| Diabetes TRAE (grade 3-4) | 1.00 [0.02, 50.65] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 2.11 [0.40, 10.96] | | < 1 | | 75% | 2 studies (2/-) | 18.9 % | some concern | not evaluable | moderate | non important | - |
| Dysgeusia TRAE (grade 3-4) | 0.49 [0.01, 24.77] | | < 1 | | 0% | 1 study (1/-) | 63.7 % | NA | not evaluable | | non important | - |
| Epistaxis TRAE (grade 3-4) | 8.09 [0.43, 153.59] | | < 1 | | 0% | 1 study (1/-) | 8.4 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 1.12 [0.67, 1.88] | | < 1 | | 0% | 2 studies (2/-) | 33.2 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 1.48 [0.85, 2.57] | | < 1 | | 0% | 1 study (1/-) | 8.2 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 8.09 [0.43, 153.59] | | < 1 | | 0% | 1 study (1/-) | 8.4 % | NA | not evaluable | | non important | - |
| Hypertension TRAE (grade 3-4) | 1.00 [0.57, 1.78] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 2.01 [0.07, 60.02] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Hypophysitis TRAE (grade 3-4) | 2.01 [0.07, 60.02] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 2.01 [0.07, 60.02] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Increase AST TRAE (grade 3-4) | 4.04 [0.45, 36.32] | | < 1 | | 0% | 1 study (1/-) | 10.8 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 4.04 [0.45, 36.32] | | < 1 | | 0% | 1 study (1/-) | 10.8 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 1.77 [0.51, 6.09] | | < 1 | | 0% | 1 study (1/-) | 18.4 % | NA | not evaluable | | non important | - |
| Myalgia TRAE (grade 3-4) | 2.01 [0.18, 22.26] | | < 1 | | 0% | 1 study (1/-) | 28.6 % | NA | not evaluable | | non important | - |
| Myositis TRAE (grade 3-4) | 2.01 [0.07, 60.02] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 1.80 [0.90, 3.58] | | < 1 | | 0% | 2 studies (2/-) | 4.8 % | some concern | not evaluable | moderate | non important | - |
| Nephritis TRAE (grade 3-4) | 2.01 [0.07, 60.02] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 1.24 [0.95, 1.62] | | < 1 | | 0% | 2 studies (2/-) | 6.0 % | some concern | not evaluable | moderate | non important | - |
| Pancreatitis TRAE (grade 3-4) | 4.03 [0.18, 89.56] | | < 1 | | 0% | 1 study (1/-) | 19.2 % | NA | not evaluable | | non important | - |
| Paraesthesia TRAE (grade 3-4) | 0.50 [0.02, 14.97] | | < 1 | | 0% | 1 study (1/-) | 65.3 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 1.23 [0.50, 3.01] | | < 1 | | 0% | 1 study (1/-) | 32.4 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 3.04 [0.61, 15.15] | | < 1 | | 0% | 1 study (1/-) | 8.8 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 10.14 [0.55, 186.27] | | < 1 | | 0% | 1 study (1/-) | 6.1 % | NA | not evaluable | | non important | - |
| Sepsis TRAE (grade 3-4) | 2.01 [0.07, 60.02] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 4.04 [0.45, 36.32] | | < 1 | | 0% | 1 study (1/-) | 10.8 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 1.24 [0.78, 1.97] | | < 1 | | 3% | 2 studies (2/-) | 18.7 % | some concern | not evaluable | moderate | non important | - |
| Vomiting TRAE (grade 3-4) | 1.32 [0.55, 3.21] | | < 1 | | 0% | 2 studies (2/-) | 26.8 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) endpoints 00 |
| hepatitis (Autoimmune) AE (grade 3-4) | 0.98 [0.03, 29.35] | | < 1 | | 0% | 1 study (1/-) | 50.4 % | NA | not evaluable | | non important | - |
| Abdominal pain AE (grade 3-4) | 1.23 [0.24, 6.38] | | < 1 | | 0% | 1 study (1/-) | 40.4 % | NA | not evaluable | | non important | - |
| Agranulocytosis (AE grade 3-4) | 0.24 [0.01, 7.31] | | < 1 | | 0% | 1 study (1/-) | 78.8 % | NA | not evaluable | | non important | - |
| Alopecia AE (grade 3-4) | 0.49 [0.01, 24.77] | | < 1 | | 0% | 1 study (1/-) | 63.7 % | NA | not evaluable | | non important | - |
| Anaemia AE (grade 3-4) | 1.47 [1.03, 2.11] | | < 1 | | 0% | 1 study (1/-) | 1.7 % | NA | not evaluable | | non important | - |
| Arthralgia AE (grade 3-4) | 7.97 [0.46, 139.30] | | < 1 | | 0% | 1 study (1/-) | 8.0 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 1.59 [0.58, 4.39] | | < 1 | | 0% | 1 study (1/-) | 18.6 % | NA | not evaluable | | non important | - |
| Back pain AE (grade 3-4) | 3.97 [0.49, 31.97] | | < 1 | | 0% | 1 study (1/-) | 9.9 % | NA | not evaluable | | non important | - |
| Blood creatinine increased AE (grade 3-4) | 1.97 [0.09, 43.77] | | < 1 | | 0% | 1 study (1/-) | 33.7 % | NA | not evaluable | | non important | - |
| Colitis AE (grade 3-4) | 2.96 [0.15, 59.25] | | < 1 | | 0% | 1 study (1/-) | 24.2 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 4.95 [0.27, 90.93] | | < 1 | | 0% | 1 study (1/-) | 14.4 % | NA | not evaluable | | non important | - |
| Cough AE (grade 3-4) | 2.96 [0.15, 59.25] | | < 1 | | 0% | 1 study (1/-) | 24.2 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 0.98 [0.33, 2.90] | | < 1 | | 0% | 1 study (1/-) | 51.4 % | NA | not evaluable | | non important | - |
| Diabetes mellitus AE (grade 3-4) | 1.97 [0.09, 43.77] | | < 1 | | 0% | 1 study (1/-) | 33.7 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 0.87 [0.44, 1.70] | | < 1 | | 0% | 1 study (1/-) | 65.8 % | NA | not evaluable | | non important | - |
| Dizziness AE (grade 3-4) | 0.49 [0.03, 7.86] | | < 1 | | 0% | 1 study (1/-) | 69.1 % | NA | not evaluable | | non important | - |
| Dry skin AE (grade 3-4) | 0.24 [0.01, 7.31] | | < 1 | | 0% | 1 study (1/-) | 78.8 % | NA | not evaluable | | non important | - |
| Dysgeusia AE (grade 3-4) | 0.49 [0.01, 24.77] | | < 1 | | 0% | 1 study (1/-) | 63.7 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 5.61 [1.31, 24.06] | | < 1 | | 0% | 1 study (1/-) | 1.0 % | NA | not evaluable | | non important | - |
| Epistaxis AE (grade 3-4) | 0.49 [0.03, 7.86] | | < 1 | | 0% | 1 study (1/-) | 69.1 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 1.28 [0.68, 2.43] | | < 1 | | 0% | 1 study (1/-) | 22.2 % | NA | not evaluable | | non important | - |
| Febrile neutropenia AE (grade 3-4) | 0.90 [0.33, 2.46] | | < 1 | | 0% | 1 study (1/-) | 58.4 % | NA | not evaluable | | non important | - |
| Gastritis AE (grade 3-4) | 1.97 [0.09, 43.77] | | < 1 | | 0% | 1 study (1/-) | 33.7 % | NA | not evaluable | | non important | - |
| Headache AE (grade 3-4) | 0.98 [0.03, 29.35] | | < 1 | | 0% | 1 study (1/-) | 50.4 % | NA | not evaluable | | non important | - |
| Hypertension AE (grade 3-4) | 1.48 [0.30, 7.38] | | < 1 | | 0% | 1 study (1/-) | 31.8 % | NA | not evaluable | | non important | - |
| Hyperthyroidism AE (grade 3-4) | 0.49 [0.03, 7.86] | | < 1 | | 0% | 1 study (1/-) | 69.1 % | NA | not evaluable | | non important | - |
| Hypothyroidism AE (grade 3-4) | 1.97 [0.09, 43.77] | | < 1 | | 0% | 1 study (1/-) | 33.7 % | NA | not evaluable | | non important | - |
| Increase AST AE (grade 3-4) | 0.98 [0.24, 3.96] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
| Increased ALT AE (grade 3-4) | 0.73 [0.20, 2.62] | | < 1 | | 0% | 1 study (1/-) | 68.4 % | NA | not evaluable | | non important | - |
| Infusion-related reaction AE (grade 3-4) | 0.98 [0.03, 29.35] | | < 1 | | 0% | 1 study (1/-) | 50.4 % | NA | not evaluable | | non important | - |
| Leucopenia AE (grade 3-4) | 1.57 [0.66, 3.73] | | < 1 | | 0% | 1 study (1/-) | 15.4 % | NA | not evaluable | | non important | - |
| Myalgia AE (grade 3-4) | 0.98 [0.03, 29.35] | | < 1 | | 0% | 1 study (1/-) | 50.4 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 1.59 [0.58, 4.39] | | < 1 | | 0% | 1 study (1/-) | 18.6 % | NA | not evaluable | | non important | - |
| Neutropenia AE (grade 3-4) | 1.24 [0.88, 1.75] | | < 1 | | 0% | 1 study (1/-) | 11.2 % | NA | not evaluable | | non important | - |
| Pancytopenia (AE grade 3-4) | 0.49 [0.07, 3.49] | | < 1 | | 0% | 1 study (1/-) | 76.1 % | NA | not evaluable | | non important | - |
| Paraesthesia AE (grade 3-4) | 1.97 [0.09, 43.77] | | < 1 | | 0% | 1 study (1/-) | 33.7 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy AE (grade 3-4) | 0.73 [0.12, 4.42] | | < 1 | | 0% | 1 study (1/-) | 63.2 % | NA | not evaluable | | non important | - |
| Peripheral oedema AE (grade 3-4) | 0.73 [0.12, 4.42] | | < 1 | | 0% | 1 study (1/-) | 63.2 % | NA | not evaluable | | non important | - |
| Peripheral sensory neuropathy AE (grade 3-4) | 0.98 [0.24, 3.96] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
| Pneumonia AE (grade 3-4) | 1.40 [0.67, 2.93] | | < 1 | | 0% | 1 study (1/-) | 18.8 % | NA | not evaluable | | non important | - |
| Pneumonitis AE (grade 3-4) | 0.24 [0.01, 7.31] | | < 1 | | 0% | 1 study (1/-) | 78.8 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 0.98 [0.03, 29.35] | | < 1 | | 0% | 1 study (1/-) | 50.4 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 0.98 [0.03, 29.35] | | < 1 | | 0% | 1 study (1/-) | 50.4 % | NA | not evaluable | | non important | - |
| Rash AE (grade 3-4) | 0.98 [0.09, 10.87] | | < 1 | | 0% | 1 study (1/-) | 50.6 % | NA | not evaluable | | non important | - |
| Rash maculopapular AE (grade 3-4) | 0.98 [0.03, 29.35] | | < 1 | | 0% | 1 study (1/-) | 50.4 % | NA | not evaluable | | non important | - |
| Sepsis AE (grade 3-4) | 6.95 [0.39, 123.09] | | < 1 | | 0% | 1 study (1/-) | 9.5 % | NA | not evaluable | | non important | - |
| Stomatitis AE (grade 3-4) | 0.24 [0.02, 2.70] | | < 1 | | 0% | 1 study (1/-) | 87.3 % | NA | not evaluable | | non important | - |
| Thrombocytopenia AE (grade 3-4) | 1.49 [0.83, 2.69] | | < 1 | | 0% | 1 study (1/-) | 9.3 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 1.28 [0.45, 3.64] | | < 1 | | 0% | 1 study (1/-) | 32.0 % | NA | not evaluable | | non important | - |
| Weight decreased AE (grade 3-4) | 0.98 [0.09, 10.87] | | < 1 | | 0% | 1 study (1/-) | 50.6 % | NA | not evaluable | | non important | - |
